The Great IPO Drought has gone on for 18 months, but some are hopeful that may be ending.
Experimental vaccine shows promise in delaying the return of aggressive brain tumor
The vaccine was shown to nearly double the survival time in a trial of 63 patients. Researchers now hope to confirm the findings in a larger trial.
Stocks making the biggest moves before the bell: Nasdaq, Illumina, Oracle, Carnival & more
These are the stocks posting the largest moves in premarket trading.
This underappreciated cybersecurity stock could rally more than 35%, Morgan Stanley says
Despite recent execution blunders, Morgan Stanley believes SentinelOne shares are now mispriced by Wall Street.
Amazon shares can rally nearly 25% as retail margins improve, Bank of America says
The bank hiked its price target on Amazon shares to $154 from $139, citing an improving outlook on retail margins.
HSBC builds innovation division from the bones of collapsed SVB UK
HSBC unveiled its new HSBC Innovation Banking unit Monday, following its eleventh-hour rescue of the U.K. subsidiary of SVB in March.
Nasdaq to acquire financial software maker Adenza for $10.5 billion
Nasdaq on Monday said it will buy Thoma Bravo-owned software firm Adenza for $10.5 billion as it speeds up its push to become a more tech-focused company.
This software stock can pop nearly 20% thanks to its early-mover advantage in A.I., Wolfe Research says
Analyst Alex Zukin raised his rating on shares to outperform from peer perform.
JPMorgan upgrades Carnival as momentum for the cruise industry grows
Carnival’s post-pandemic recovery is not just a short-term boom, but an indication of more sustainable business strength, says JPMorgan.
Drug trial results could boost 2 Club pharma stocks. Here’s what to expect
Eli Lilly and Johnson & Johnson are set to present fresh drug-trial data at a conference later this month.
- « Previous Page
- 1
- …
- 853
- 854
- 855
- 856
- 857
- …
- 1899
- Next Page »